Stock TRX TISSUE REGENIX GROUP PLC
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Tissue Regenix Group plc

Equities

TRX

GB00BNTXR104

Delayed London S.E.
Other stock markets
 10:57:06 27/06/2024 BST 		5-day change 1st Jan Change
64.6 GBX -1.37% Intraday chart for Tissue Regenix Group plc -0.62% +24.23%
06-14 Tissue Regenix purchases Texas facility to generate cost savings AN
06-14 Tissue Regenix Buys Leased Property in Texas MT

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach -96% by 2026.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
TISSUE REGENIX GROUP PLC Stock Tissue Regenix Group plc
+24.23% 58.9M -
VEEVA SYSTEMS INC. Stock Veeva Systems Inc.
-4.29% 29.79B
C
PRO MEDICUS LIMITED Stock Pro Medicus Limited
+45.89% 9.69B
C-
SECTRA AB Stock Sectra AB
+35.91% 4.5B
B-
EVOLENT HEALTH, INC. Stock Evolent Health, Inc.
-37.06% 2.38B
C-
VERADIGM INC. Stock Veradigm Inc.
-8.01% 1.63B -
C+
OMNICELL, INC. Stock Omnicell, Inc.
-30.32% 1.2B
B
SIMULATIONS PLUS, INC. Stock Simulations Plus, Inc.
+6.59% 953M
C
LUNIT INC. Stock Lunit Inc.
-41.51% 992M -
B-SOFT CO.,LTD. Stock B-SOFT Co.,Ltd.
-45.19% 763M -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. TRX Stock
  4. Ratings Tissue Regenix Group plc